Found: 1
Select item for more details and to access through your institution.
The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 2, p. 238, doi. 10.3390/pharmaceutics14020238
- By:
- Publication type:
- Article